Haasio K, Nissinen E, Sopanen L, Heinonen E H
Orion Corporation, Orion Pharma, Espoo, Finland.
J Neural Transm (Vienna). 2002 Nov;109(11):1391-401. doi: 10.1007/s00702-002-0748-x.
The toxicity profiles of entacapone and tolcapone, novel catechol- O-methyl-transferase (COMT) inhibitors, have been reported to differ from each other. It has also been shown that tolcapone, but not entacapone, is a potent uncoupler of oxidative phosphorylation in vitroat low micromolar concentrations. Signs of hepatotoxicity induced by tolcapone treatment have been previously reported in toxicological studies and in clinical use. The present study was designed to investigate the mechanism of hepatotoxicity of tolcapone and its possible relationship to uncoupling of oxidative phosphorylation in vivo. A 15-day oral toxicity study with entacapone or tolcapone (300 and 500 mg/kg/day) was carried out, and 2, 4-dinitrophenol (DNP), a known uncoupling agent of oxidative phosphorylation, served as a positive reference substance (20 mg/kg/day). No treatment related findings were observed in entacapone-treated rats. Clinical chemistry parameters regarding hepatocellular damage were increased in tolcapone and DNP-treated animals. The energy status measured as ATP/ADP ratio from the liver samples and energy charge (EC) in liver cell mitochondria were diminished both in tolcapone- and in DNP-treated rats. These signs together with clinical symptoms consisting of increased respiration, decreased activity and drowsiness, and elevation of the rectal body temperature observed in tolcapone- and DNP-treated animals suggest a relationship between the treatment and uncoupling of oxidative phosphorylation in vivo.
据报道,新型儿茶酚-O-甲基转移酶(COMT)抑制剂恩他卡朋和托卡朋的毒性特征有所不同。研究还表明,在低微摩尔浓度下,托卡朋而非恩他卡朋在体外是一种有效的氧化磷酸化解偶联剂。此前在毒理学研究和临床应用中已有托卡朋治疗引起肝毒性迹象的报道。本研究旨在探究托卡朋肝毒性的机制及其与体内氧化磷酸化解偶联的可能关系。进行了一项为期15天的口服毒性研究,分别给予恩他卡朋或托卡朋(300和500毫克/千克/天),已知的氧化磷酸化解偶联剂2,4-二硝基苯酚(DNP)作为阳性对照物质(20毫克/千克/天)。在恩他卡朋治疗的大鼠中未观察到与治疗相关的异常。在托卡朋和DNP治疗的动物中,与肝细胞损伤相关的临床化学参数升高。在托卡朋和DNP治疗的大鼠中,肝脏样本中以ATP/ADP比值衡量的能量状态以及肝细胞线粒体中的能荷(EC)均降低。这些迹象连同在托卡朋和DNP治疗的动物中观察到的包括呼吸加快、活动减少、嗜睡以及直肠体温升高在内的临床症状表明,治疗与体内氧化磷酸化解偶联之间存在关联。